Cannabinoid Drug Interactions: Clinical Evidence Review
Comments Off on Cannabinoid Drug Interactions: Clinical Evidence Review
April 25, 2026
Clinical Takeaway CBD commonly inhibits cytochrome P450 enzymes at high doses, potentially increasing levels of medications metabolized through CYP3A4, CYP2C19, and CYP2C9, though clinical significance varies by individual patient factors and CBD dosing.…
Cannabis Meets Drug Metabolism: What We Know—and Don’t Know—About Cannabinoids and CYP450 Enzymes
Comments Off on Cannabis Meets Drug Metabolism: What We Know—and Don’t Know—About Cannabinoids and CYP450 Enzymes
April 9, 2026
Recognising potential interactions between cannabinoids and other drugs could enhance understanding of their pharmacological effects, improve the efficacy and safety profiles of cannabinoid-based therapies, and encourage further exploration into this…
Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.
Comments Off on Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.
March 25, 2026
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemica...